Washington Trust Advisors’s Biogen BIIB Stock Holding History

Washington Trust Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-134	Closed	-$26K	–	650
2024 Q3	$26K	Sell	134 -17	-11%	-$3.56K	﹤0.01%	392
2024 Q2	$35K	Buy	151 +57	+61%	+$12.4K	﹤0.01%	351
2024 Q1	$20.3K	Buy	94 +8	+9%	+$1.87K	﹤0.01%	399
2023 Q4	$22.3K	Hold	86	–	–	﹤0.01%	387
2023 Q3	$22.1K	Hold	86	–	–	﹤0.01%	383
2023 Q2	$24.5K	Sell	86 -110	-56%	-$32.7K	﹤0.01%	364
2023 Q1	$54.5K	Sell	196 -6	-3%	-$1.66K	0.01%	299
2022 Q4	$55.9K	Sell	202 -399	-66%	-$113K	0.01%	299
2022 Q3	$160K	Sell	601 -51	-8%	-$10.8K	0.02%	219
2022 Q2	$133K	Sell	652 -343	-34%	-$70.1K	0.01%	254
2022 Q1	$210K	Sell	995 -156	-14%	-$33.9K	0.01%	229
2021 Q4	$276K	Buy	+1,151	New	+$296K	0.02%	215

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Washington Trust Advisors's BIIB Position: Q4 2024 in Review

Washington Trust Advisors sold out of Biogen (BIIB) in Q4 2024, closing a stake of 134 shares — an estimated $26K sold.

Washington Trust Advisors first reported a position in BIIB in Q4 2021 and held it in 12 quarters. The position peaked at $276K in Q4 2021. 876 funds tracked by Wall St. Rank hold BIIB as of Q4 2024.

Washington Trust Advisors reported no remaining Biogen position as of Q4 2024 after selling out during the quarter.
Washington Trust Advisors sold 134 Biogen shares in Q4 2024, an estimated $26K.
Washington Trust Advisors first reported a position in Biogen in Q4 2021 and held it in 12 quarters.
Washington Trust Advisors's Biogen position peaked at $276K in Q4 2021.
876 funds tracked by Wall St. Rank held Biogen as of Q4 2024.

Based on Washington Trust Advisors's 13F filing for Q4 2024, filed 6 Feb 2025.